Recombinant Hormone Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The market is segmented By Product Type (Growth Hormone, Insulin, Follicle-stimulating Hormone, Other Products) and Geography.

Market Snapshot

Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 6.4 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Recombinant Hormone Market is expected to register a CAGR of 6.4% during the forecast period. The recombinant hormone is the hormone made in a laboratory using recombinant technology which is used for therapeutic purposes. The endocrine system in the human body consists of glands (pituitary gland, thyroid gland, parathyroid glands, adrenal glands, pancreas, etc.) that produce hormones and regulate different functions such as metabolism, growth and development, reproduction, sexual function, tissue function, mood, and sleep, among other functions. If hormone levels are too high or too low indicate a problem with the endocrine system. In the human body, peptide hormones are secreted after encoding by peptide hormone genes in the specialized cells, such as insulin and another human growth hormone.

The most common endocrine disease in the United States is diabetes, a condition in which the body does not produce glucose, and this is due to the lack of insulin or it may be the body that is not working effectively with produced insulin. Some of the common endocrine disorders are Type 1 and Type 2 Diabetes, Osteoporosis, Thyroid Cancer, Addison’s Disease, etc.

According to International Diabetes Federation, approximately 463 million adults were living with diabetes in the year 2019 and by the year 2045 this will rise to 700 million worldwide and 79% of adults with diabetes are from low- and middle-income countries.

Technological advancements in the development of recombinant hormone therapies, hormonal disorders with rising geriatric population are the key driving factors in the recombinant hormone market.

Scope of the Report

The recombinant hormone is the hormone made in a laboratory using recombinant technology which is used for therapeutic purposes. Recombinant Hormone Market is segmented By Product Type and Geography.

By Product Type
Growth Hormone
Follicle-stimulating Hormone
Other Products
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Insulin Segment is Expected to Hold a Major Market Share in the Recombinant Hormone Market

  • The insulin hormone is secreted by the beta cells of Islets of Langerhans of the pancreas which catabolizes glucose in the blood. Insulin helps to keep blood sugar level from getting too high (hyperglycemia) or too low (hypoglycemia).
  • According to the International Diabetes Federation, globally, about 374 million people are at increased risk of developing type 2 diabetes and more than 1.1 million children and adolescents are living with type 1 diabetes. In addition, deaths due to diabetes were about 4.2 million in the year 2019.
  • Approximately 100 million people around the world are in need of insulin, including people with Type 1 diabetes and Type 2 diabetes. In addition, insulin has been used in the treatment of diabetes for over 90 years, globally, more than half of those who need insulin today still cannot afford and access it. 
  • Rising incidence of diabetes and technological advancements in recombinant insulin hormones are the key driving factors in the insulin segment.
Recombinant Hormone Therapy Key trend 1

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global recombinant hormone market due to increasing incidence of hormonal disorders. Moreover, companies investing in research and development for developing a growth hormone that has fewer side effects and will be long-acting hormonal in this region.

According to Centers for Disease Control and Prevention, more than 30 million Americans have diabetes and 84 million United States adults have prediabetes. In addition, in the year 2017, the total estimated cost of diagnosed diabetes was about 327 billion dollars, including 237 billion in medical costs and 90 billion in reduced productivity. Furthermore, technological advancements in recombinant hormonal therapies, increasing healthcare spending and presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Reconbi trend 2

Competitive Landscape

The Recombinant Hormone Market is consolidated competitive and consists of few major players. In terms of market share, few of the major players are currently dominating the market. Collaborations and mergers over the next coming years to share technology and increasing investments for innovation in the field are expected to be observed. Some of the companies which control significant market share include Eli Lilly and Company, Ferring Pharmaceuticals, Hoffmann La Roche Ltd (Genentech, Inc), Merck & Co Inc, Pfizer Inc, Novo Nordisk A/S, Novartis AG (Sandoz International GmbH), Ipsen Pharma, LG Life Sciences and Teva Pharmaceutical Industries.

Table of Contents


    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Incidence of Growth Disorders and Diabetes

      2. 4.2.2 Technological Advancements in Development of Recombinant Hormonal Therapies

    3. 4.3 Market Restraints

      1. 4.3.1 Adverse Effects Associated with Recombinant Hormonal Therapies

      2. 4.3.2 Stringent Regulatory Processes

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Product Type

      1. 5.1.1 Growth Hormone

      2. 5.1.2 Insulin

      3. 5.1.3 Follicle-stimulating Hormone

      4. 5.1.4 Other Products

    2. 5.2 Geography

      1. 5.2.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.2.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.2.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.2.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.2.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Eli Lilly and Company

      2. 6.1.2 Ferring Pharmaceuticals

      3. 6.1.3 F.Hoffmann-La Roche Ltd (Genentech

      4. 6.1.4 Merck & Co Inc

      5. 6.1.5 Pfizer Inc

      6. 6.1.6 Novo Nordisk A/S

      7. 6.1.7 Novartis AG (Sandoz International GmbH)

      8. 6.1.8 Ipsen Pharma

      9. 6.1.9 LG Life Sciences

      10. 6.1.10 Teva Pharmaceutical Industries

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Recombinant Hormone Market market is studied from 2018 - 2026.

The Recombinant Hormone Market is growing at a CAGR of 6.4% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Eli Lilly and Company, Ferring Pharmaceuticals, F.Hoffmann-La Roche Ltd (Genentech, Inc), Merck & Co Inc (Merck KGaA), Pfizer Inc are the major companies operating in Recombinant Hormone Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!